New drug aims to stop nosebleeds in rare genetic disorder
Disease control
Ongoing
This study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The first part compares two doses of VAD044 against a placebo to see if it safely reduces the number, length, and sever…
Phase: PHASE1, PHASE2 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC